Your liver does not complain. Know two numbers, and sleep easy.
Understand what "fatty liver" means, learn your stage from two tests you already have, and walk into your appointment with a clear record.

The current scientific name is MASLD (metabolic dysfunction-associated steatotic liver disease), adopted in 2023 in place of NAFLD and "non-alcoholic fatty liver". The name changed because the real cause is metabolic dysfunction, not the "absence of alcohol"; you may still find the old name in your reports.

The disease has grades: fat alone (steatosis) in the majority, then inflammation with fat (MASH) in a minority, then fibrosis that accumulates over years in a minority of those. Most people with a fatty liver will never reach advanced fibrosis, but those who do cannot tell from their symptoms.

About a third of adults worldwide are estimated to have a fatty liver; the proportion is higher in people with type 2 diabetes or obesity.

Limits: The words "fatty liver" on an imaging report do not by themselves say the grade; the grade comes from the tests the doctor chooses.

Sources: Delphi consensus (Hepatology) (2023) · EASL–EASD–EASO (2024) · NIDDK (2021)

Even moderate fibrosis usually causes no symptoms. Some people report tiredness or a heavy feeling under the right ribs, but that neither measures the grade nor rules it out.

Symptoms appear very late, with decompensated cirrhosis: jaundice, abdominal fluid, bleeding, confusion. That is why the doctor does not wait for symptoms but estimates risk from numbers.

The good news: because the disease is slow and silent, time is on your side if you learn your grade early.

Limits: No symptoms does not mean no fibrosis, and tiredness does not mean fibrosis is present.

Sources: NIDDK (2021) · NHS (2022) · AASLD (2023)

Type 2 diabetes is the strongest factor: about two thirds of people with diabetes have a fatty liver, and advanced fibrosis is far more common in them than in others.

Obesity alone means a fatty liver in many people, but what raises the chance of fibrosis is two or more factors together: a large waist, high blood pressure, high triglycerides, low HDL cholesterol, or raised fasting glucose.

An incidental rise in ALT or AST, even mild and persistent, needs an explanation, not a repeat test in a year. A fatty liver is the commonest explanation, but not the only one.

If you drink alcohol the picture differs: the doctor estimates the amount, because the course and the name change.

Limits: Your doctor decides on testing from your factors; this page helps you know whether you are someone the question applies to.

Sources: EASL–EASD–EASO (2024) · AASLD (2023)

Below 1.3: the chance of advanced fibrosis is low; re-estimating every one to three years according to your factors is enough. (At 65 and over the cut-off is 2.0, because age raises the number by itself.)

Above 2.67: a higher chance that needs a more precise assessment, usually a FibroScan and referral to a liver specialist.

Between 1.3 and 2.67: a grey zone; the next step is a FibroScan or a blood fibrosis test (such as ELF) so the doctor can decide.

FIB-4 is a triage tool, not a diagnosis: a low number reassures more than a high number confirms. That is why SADA shows no home calculator; the meaning comes with your doctor.

Limits: Cut-offs are from the EASL 2024 guideline; interpreting your own number is done with your doctor.

Sources: EASL–EASD–EASO (2024) · AASLD (2023)

Stiffness below 8 kPa excludes advanced fibrosis in most people. 8 to 12 is a zone that needs interpretation. 12 and above suggests advanced fibrosis and needs a liver specialist.

A FibroScan reading is affected by eating beforehand (3 hours of fasting are needed), acute inflammation and severe obesity, so the doctor reads it with ALT and the whole picture, not as a lone number.

MRI (MRI-PDFF or MRE) is more precise but costlier and less available, requested in specific cases or in research.

Biopsy is the only test that sees the inflammation (MASH) directly; it is requested when tests conflict, when another liver disease is suspected, or before some of the newer medicines.

Limits: kPa cut-offs are indicative, from EASL 2024, and vary by device and context; do not compare your number with someone else's.

Sources: EASL–EASD–EASO (2024) · AASLD (2023) · NIDDK (2021)

F0–F1: no or mild fibrosis; the goal is preventing progression, with follow-up every one to three years.

F2: significant fibrosis; here liver-directed medicines are discussed alongside lifestyle change, with closer follow-up.

F3: advanced fibrosis before cirrhosis; needs a liver specialist, with screening for oesophageal varices and liver cancer according to assessment.

F4: cirrhosis. Even here, compensated cirrhosis without symptoms can stay stable for many years with regular follow-up: endoscopy for varices and imaging every six months to catch liver cancer early.

Limits: The stage is set by the doctor's tests; FIB-4 and FibroScan estimate it without matching it exactly.

Sources: AASLD (2023) · EASL–EASD–EASO (2024) · NHS (2022)

For someone weighing 100 kg: 5 kg improves the fat, 7 kg the inflammation, 10 kg the fibrosis. Reaching an "ideal weight" is not required; what matters is a steady direction that is maintained.

Speed is not the goal: half a kilo to a kilo a week is enough, and very fast loss (more than 1.5 kg a week) can temporarily raise enzymes and increase gallstones.

In people of normal weight who nevertheless have a fatty liver (about one in five), a 3–5% loss and better body composition through activity also help.

Weight-loss injections and bariatric surgery are ways of reaching these numbers for those who medically qualify; the details are in the قَوام centre and in the medicines section here.

Limits: The percentages are guideline averages; your liver's response is measured by your tests and FibroScan, not by the scales alone.

Sources: EASL–EASD–EASO (2024) · AASLD (2023) · NIDDK (2021)

The Mediterranean pattern: vegetables, legumes, whole grains, olive oil and fish, with little red or processed meat. It improves liver fat even without major weight loss.

Sugary drinks and packaged fruit juices are the worst thing for a fatty liver, because fructose turns into fat in the liver directly. Stopping them alone is a measurable step.

Coffee: regular coffee (without sugar and cream) is associated with a lower risk of fibrosis in many studies, and the EASL guideline mentions it as a helpful habit for those who tolerate it. About three cups a day is what the studies centre on.

Movement: 150 minutes a week of brisk walking or the equivalent, plus resistance exercise twice a week; movement reduces liver fat even if the weight does not change.

Alcohol: with a fatty liver any amount adds harm; the guidance is clear: complete avoidance when fibrosis is present.

Limits: No single diet for everyone and no "liver cleanse" supplement; most products marketed under that name have no evidence and some harm the liver.

Sources: EASL–EASD–EASO (2024) · AASLD (2023) · WHO (2020) · NHS (2022)

Semaglutide (the weekly weight-loss injection) was approved by the FDA for MASH with moderate to advanced fibrosis after it was shown to regress inflammation and fibrosis. The injection people ask you about for weight has become a liver treatment for those who qualify.

Resmetirom: a daily tablet acting on thyroid-hormone receptors in the liver, approved in March 2024 specifically for MASH with F2–F3, not for fat alone and not for cirrhosis.

Pioglitazone (a diabetes medicine) and vitamin E (800 IU daily for people without diabetes) are two older options the AASLD guidance suggests for selected cases of biopsy-proven MASH, with their cautions.

Statins (cholesterol medicines) are safe and important for people with fatty liver, because what these patients most often die of is the heart, not the liver. A mild rise in liver enzymes is not a reason to stop them.

What does not help: "liver cleanses", high-dose black seed, herbal mixtures and most supplements — some are documented causes of liver injury.

The medicine map: for whom, how it is taken, and its usual pattern ↓

Limits: Names and patterns here are from the labels; who qualifies for any medicine, and on what condition, is decided by your doctor after the stage is set.

Sources: EASL–EASD–EASO (2024) · AASLD (2023) · FDA (2024) · FDA label (DailyMed) (2025) · FDA label (DailyMed) (2024) · BNF (NICE) (2026)

Do not wait for the usual appointment: yellowing of the eyes or skin, new abdominal fluid or leg swelling, vomiting blood or black stools, unusual confusion or drowsiness, or rapid unintended weight loss with severe tiredness.

Contact your doctor within weeks: a new and clear rise in liver enzymes, persistent pain under the right ribs, generalised itching without a rash, or a new medicine or supplement after which your tests changed.

Usual follow-up: FIB-4 or FibroScan every one to three years at low stages, closer from F2 upward, with control of sugar, blood pressure and lipids, because they are managed together.

Limits: The signs above are from NIDDK and NHS; assessing any of them happens in the emergency department or with your doctor, not here.

Sources: NIDDK (2021) · NHS (2022) · EASL–EASD–EASO (2024)